Thomas Berger

Summary

Affiliation: University of Innsbruck
Country: Austria

Publications

  1. ncbi Multiple sclerosis
    Thomas Berger
    Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A 6020, Innsbruck, Austria
    Autoimmunity 37:321-4. 2004
  2. ncbi Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event
    Thomas Berger
    Department of Neurology, University of Innsbruck, Innsbruck, Austria
    N Engl J Med 349:139-45. 2003
  3. pmc Biomarkers in multiple sclerosis: role of antibodies
    Thomas Berger
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Dis Markers 22:207-12. 2006
  4. ncbi Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments
    Michael Khalil
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Neuroimmunol 174:147-56. 2006
  5. ncbi Increased serum levels of soluble CD14 indicate stable multiple sclerosis
    Andreas Lutterotti
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Neuroimmunol 181:145-9. 2006
  6. doi Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases
    Viktoria Gredler
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    J Neurol Sci 328:77-82. 2013
  7. pmc Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
    Simone Mader
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    J Neuroinflammation 8:184. 2011
  8. doi Elevated γ-glutamyltransferase in implantable cardioverter defibrillator patients
    Wolfgang Dichtl
    Clinic for Internal Medicine III, Cardiology, Medical University Innsbruck, Innsbruck, Austria
    Wien Klin Wochenschr 124:18-24. 2012
  9. doi Features of intrathecal immunoglobulins in patients with multiple sclerosis
    Franziska Di Pauli
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Neurol Sci 288:147-50. 2010
  10. doi Persistency of neutralizing antibodies depends on titer and interferon-beta preparation
    Harald Hegen
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mult Scler 18:610-5. 2012

Detail Information

Publications61

  1. ncbi Multiple sclerosis
    Thomas Berger
    Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A 6020, Innsbruck, Austria
    Autoimmunity 37:321-4. 2004
  2. ncbi Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event
    Thomas Berger
    Department of Neurology, University of Innsbruck, Innsbruck, Austria
    N Engl J Med 349:139-45. 2003
    ....
  3. pmc Biomarkers in multiple sclerosis: role of antibodies
    Thomas Berger
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Dis Markers 22:207-12. 2006
    ..The present review summarizes the presentation on the potential role of antibodies as biomarkers for diagnosis, disease activity, classification and prediction of clinical courses in multiple sclerosis...
  4. ncbi Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments
    Michael Khalil
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Neuroimmunol 174:147-56. 2006
    ..Recently experienced relapses intensified the anti-MOG peptide antibody response. Immunomodulatory treatment with interferon-beta or glatiramer-acetate had no major impact on the anti-MOG peptide immunoreactivity after 1 year of therapy...
  5. ncbi Increased serum levels of soluble CD14 indicate stable multiple sclerosis
    Andreas Lutterotti
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Neuroimmunol 181:145-9. 2006
    ..An increased expression of sCD14 was also detected after treatment with interferon-beta. In summary, we report evidence that serum sCD14 levels are increased in MS and correlate inversely with disease activity in relapsing MS patients...
  6. doi Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases
    Viktoria Gredler
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    J Neurol Sci 328:77-82. 2013
    ..Relapses were not associated with re-emerging B-cells, serum levels of B-cell activating factor (BAFF) or AQP4-IgG titers. BAFF serum levels increased following rituximab treatment...
  7. pmc Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
    Simone Mader
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    J Neuroinflammation 8:184. 2011
    ....
  8. doi Elevated γ-glutamyltransferase in implantable cardioverter defibrillator patients
    Wolfgang Dichtl
    Clinic for Internal Medicine III, Cardiology, Medical University Innsbruck, Innsbruck, Austria
    Wien Klin Wochenschr 124:18-24. 2012
    ..Elevated γ-glutamyltransferase (GGT) is a new risk factor for cardiovascular diseases, but its impact on ventricular tachyarrhythmia occurrence and survival in patients with an implantable cardioverter defibrillator (ICD) is unknown...
  9. doi Features of intrathecal immunoglobulins in patients with multiple sclerosis
    Franziska Di Pauli
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Neurol Sci 288:147-50. 2010
    ..Finally, intrathecal IgG production (IgG1 and IgG3) correlated with the presence of mature B cells and plasma blasts...
  10. doi Persistency of neutralizing antibodies depends on titer and interferon-beta preparation
    Harald Hegen
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mult Scler 18:610-5. 2012
    ..Neutralizing antibodies (NAbs) affect the efficacy of interferon-beta (IFNβ) treatment in multiple sclerosis (MS) patients, particularly if NAbs persist. Persistency depends on NAb titers, which differ between IFNβ preparations...
  11. doi B cells and antibodies in MS
    Markus Reindl
    Neuroimmunological and Multiple Sclerosis Clinic and Research Unit, Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Results Probl Cell Differ 51:99-113. 2010
    ..This chapter therefore aims to summarize the present knowledge and to outline future directions about the role of B cells and antibodies in research and therapy of MS and NMO...
  12. doi Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases
    Franziska Di Pauli
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Clin Immunol 138:247-54. 2011
    ....
  13. pmc Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis
    Bettina Kuenz
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    PLoS ONE 3:e2559. 2008
    ..There is accumulating evidence from immunological, pathological and therapeutic studies that B cells are key components in the pathophysiology of multiple sclerosis (MS)...
  14. ncbi Antibodies as biological markers for pathophysiological processes in MS
    Markus Reindl
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Neuroimmunol 180:50-62. 2006
    ..We believe that antibodies serving as biomarkers will help to establish a differential therapeutic concept in MS, which will allow to treat individuals selectively according to their pathogenetic subtype and disease status...
  15. doi Replication study of multiple sclerosis (MS) susceptibility alleles and correlation of DNA-variants with disease features in a cohort of Austrian MS patients
    Mascha C Schmied
    Department of Neurology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Neurogenetics 13:181-7. 2012
    ..01), rs7090530 (IL2RA, p < 0.026) and rs1841770 (ZIC1, p < 0.017) with a younger age at MS onset and of rs12044852 (CD58, p < 0.035) with shorter time to reach EDSS6...
  16. doi Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study
    Claudia Gneiss
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mult Scler 15:1481-8. 2009
    ..Baseline and final neutralizing antibody titres correlated significantly. In conclusion, neither switching nor continuous therapy with any subcutaneous interferon-beta preparation significantly changed neutralizing antibody titres...
  17. ncbi Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders
    Markus Reindl
    Department of Neurology, University of Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria
    J Neuroimmunol 145:139-47. 2003
    ..We finally demonstrate that human anti-Nogo-A antibodies recognize native Nogo-A in brain extracts, oligodendrocytes and cells expressing human Nogo-A...
  18. pmc Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica
    Simone Mader
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    PLoS ONE 5:e10455. 2010
    ..Serum NMO-IgG autoantibodies (Abs), a specific finding in NMO patients, target the water channel protein aquaporin-4 (AQP4), which is expressed as a long (M-1) or a short (M-23) isoform...
  19. ncbi Biological markers for multiple sclerosis
    Andreas Lutterotti
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Curr Med Chem 14:1956-65. 2007
    ....
  20. doi Natalizumab treatment reduces endothelial activity in MS patients
    Alban Millonig
    Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    J Neuroimmunol 227:190-4. 2010
    ..Correspondingly Natalizumab diminished VLA-4 on leukocyte subsets. Our findings indicate that Natalizumab reduces transmigration not only by blocking VLA-4 but also by down-regulating VCAM-1...
  21. pmc Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis
    Rainer Ehling
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    Fluids Barriers CNS 8:25. 2011
    ..abstract:..
  22. doi Impact of human myelin on the maturation and function of human monocyte-derived dendritic cells
    Viktoria Gredler
    Clinical Department of Neurology, Innsbruck Medical University, Austria
    Clin Immunol 134:296-304. 2010
    ..We hypothesize that myelin influences DC activation and plays a pivotal role in balancing immunity and tolerance...
  23. pmc Antibodies to myelin oligodendrocyte glycoprotein in HIV-1 associated neurocognitive disorder: a cross-sectional cohort study
    Peter Lackner
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    J Neuroinflammation 7:79. 2010
    ..This cross-sectional cohort study explores the potential role of antibodies to myelin oligodendrocyte glycoprotein (MOG), a putative autoantigen in multiple sclerosis, in the pathogenesis of HAND...
  24. ncbi Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis
    Bettina Kuenz
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Neuroimmunol 167:143-9. 2005
    ..These findings indicate that sPECAM-1, sP-selectin and sE-selectin might be implemented as paraclinical markers of disease activity in MS with restriction to the clinical course of the disease...
  25. ncbi Intrathecal anti-alphaB-crystallin IgG antibody responses: potential inflammatory markers in Guillain-Barré syndrome
    Julia Wanschitz
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    J Neurol 255:917-24. 2008
    ..To address the role of alphaBC in Guillain-Barré syndrome (GBS) we analyzed humoral responses against alphaBC in relation to clinical, electrophysiological and CSF features in GBS...
  26. ncbi Epitope specificity of neutralizing antibodies against IFN-beta
    Claudia Gneiss
    Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
    J Interferon Cytokine Res 24:283-90. 2004
    ..Our results indicate a qualitative and quantitative difference between NAb and NNAb, with special emphasis on the recognition of different epitopes...
  27. ncbi Antibody response to myelin oligodendrocyte glycoprotein and myelin basic protein depend on familial background and are partially associated with human leukocyte antigen alleles in multiplex families and sporadic multiple sclerosis
    Andreas Lutterotti
    Department of Neurology, University of Innsbruck, Anichstrasse 35, A 6020, Innsbruck, Austria
    J Neuroimmunol 131:201-7. 2002
    ..We conclude that antibody responses to MOG and MBP depend on familial background. Moreover, the humoral immune reactivity against MOG is partially under control of certain HLA class II alleles...
  28. doi Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis
    Kevin Rostasy
    Division of Pediatric Neurology and Inherited Metabolic Disorders, Department of Pediatrics IV, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Arch Neurol 69:752-6. 2012
    ..To study the humoral immune response directed at myelin oligodendrocyte glycoprotein (MOG)in pediatric patients with isolated and recurrent optic neuritis(ON)...
  29. ncbi Multiple sclerosis - established and novel therapeutic approaches
    Rainer Ehling
    Clinical Department of Neurology, Innsbruck Medical University, Austria
    Cent Nerv Syst Agents Med Chem 10:3-15. 2010
    ..This will pave the way for an optimized treatment approach, which will likely need both to target inflammation and to focus on promotion of neuroprotection and repair...
  30. doi Current therapeutic recommendations in multiple sclerosis
    Thomas Berger
    Neuroimmunological and Multiple Sclerosis Clinic and Research Unit, Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    J Neurol Sci 287:S37-45. 2009
    ....
  31. doi The spectrum of MOG autoantibody-associated demyelinating diseases
    Markus Reindl
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    Nat Rev Neurol 9:455-61. 2013
    ..This Review article discusses the current literature on MOG antibodies, their potential clinical relevance, and their role in the pathogenesis of MOG antibody-associated demyelinating disorders. ..
  32. pmc Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people
    Fahmy Aboul-Enein
    Department of Neurology, Sozialmedizinisches Zentrum Ost Donauspital, Vienna, Austria Department of Neurology, Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Vienna, Austria
    PLoS ONE 8:e79649. 2013
    ..Their aim was to detect all patients with NMO or NMO spectrum disorders (NMO-SD) in Austria and to analyse their disease courses and response to treatment...
  33. ncbi Is there a rationale for therapeutic immunoadsorption in multiple sclerosis?
    Thomas Berger
    Innsbruck Medical University, Innsbruck, Austria
    Eur J Clin Invest 35:467-8. 2005
  34. ncbi Multiple sclerosis: disease biomarkers as indicated by pathophysiology
    Thomas Berger
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Neurol Sci 259:21-6. 2007
    ..Antibodies (and other molecules) serving as biomarkers will help to establish a differential therapeutic concept in MS, which should allow to treat individuals selectively according to their pathogenetic subtype and disease status...
  35. ncbi Duration of the A(H)-A(Md) interval predicts occurrence of AV-block after radiofrequency ablation of the slow pathway
    Markus C Stühlinger
    Department of Internal Medicine III Cardiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
    J Interv Card Electrophysiol 31:207-15. 2011
    ..We sought to evaluate the predictive value of the A(H)-A(Md) interval-the electrical delay between atrial signals on the His- and the ablation-catheter-upon development of AVB during SP ablation...
  36. ncbi The effect of nabilone on neuropsychological functions related to driving ability: an extended case series
    Ilsemarie Kurzthaler
    Department of Biological Psychiatry, Innsbruck University Clinics, Austria
    Hum Psychopharmacol 20:291-3. 2005
    ..No indication was found of a deterioration of any of the five investigated neuropsychological functions during the 4-week treatment period with nabilone...
  37. ncbi Single-beat noninvasive imaging of cardiac electrophysiology of ventricular pre-excitation
    Thomas Berger
    Department of Internal Medicine, Division of Cardiology, Medical University Innsbruck, Innsbruck, Austria
    J Am Coll Cardiol 48:2045-52. 2006
    ....
  38. ncbi The influence of high versus normal impedance ventricular leads on pacemaker generator longevity
    Thomas Berger
    Department of Internal Medicine, Division of Cardiology, University Hospital Innsbruck, Leopold Franzens University Innsbruck, Austria
    Pacing Clin Electrophysiol 26:2116-20. 2003
    ..3 +/- 8.5 vs 97.6 +/- 9.0 months; P = 0.02). In conclusion, implantation of a high impedance lead for ventricular pacing results in a clinically relevant extension of generator longevity...
  39. doi Multiple sclerosis spasticity daily management: retrospective data from Europe
    Thomas Berger
    Neuroimmunological and Multiple Sclerosis Clinic and Research Unit, Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Expert Rev Neurother 13:3-7. 2013
    ..Consequently, newer drugs that can provide better symptomatic relief and may slow progression to more severe forms of disability will be a step forward in the level of care that we can provide for MS patients...
  40. doi Diagnostic biomarkers in multiple sclerosis
    Bettina Kuenz
    Innsbruck Medical University, Clinical Department of Neurology, Anichstrasse 35, A 6020 Innsbruck, Austria 43 512 504 24363 43 512 504 24266
    Expert Opin Med Diagn 1:225-33. 2007
    ....
  41. ncbi Daytime sleepiness is not increased in mild to moderate multiple sclerosis: a pupillographic study
    Birgit Frauscher
    Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
    Sleep Med 6:543-7. 2005
    ..In this study, we investigated daytime sleepiness in a general sample of MS patients compared to healthy controls with the pupillographic sleepiness test (PST) and the Epworth and Stanford sleepiness scales (ESS, SSS)...
  42. doi Long-term results of high vs. normal impedance ventricular leads on actual (Real-Life) pacemaker generator longevity
    Kakhaber Etsadashvili
    Clinical Department of Cardiology, Medical University Innsbruck Anichstrasse, Innsbruck, Austria
    Europace 11:200-5. 2009
    ..The long-term effects of high impedance vs. standard impedance pacing leads on actual generator longevity were studied...
  43. pmc Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group
    Franz Fazekas
    Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, Austria
    Wien Med Wochenschr 162:354-66. 2012
    ..During treatment, attention has to be given to specific infections, elevated liver enzymes, and ophthalmologic changes. Recommendations on the use of fingolimod including safety aspects are given in this article...
  44. ncbi Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial
    Jorg Wissel
    Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria
    J Neurol 253:1337-41. 2006
    ..Nabilone 1 mg per day proved to be a safe and easily applicable option in the care of patients with chronic UMNS and spasticity-related pain otherwise not controllable...
  45. ncbi Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: Case report and review of the literature
    Franziska Di Pauli
    Clinical Department of Neurology, Innsbruck Medical University, Anichstr 35, 6020 Innsbruck, Austria Electronic address
    J Clin Virol 60:424-7. 2014
    ..Due to further clinical progression with global aphasia, blindness and severe right-sided hemiparesia, medication was stopped. The Patient died three and a half months after onset of symptoms. ..
  46. ncbi Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy
    Michael F H Schocke
    Department of Radiology, the University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria
    Neuroimage 20:1253-63. 2003
    ..We believe that combined contrast-enhanced MRI and 1H MRSI may help to further investigate inflammatory processes within active MS lesions and should be employed more frequently to the research on therapy effects in MS...
  47. doi Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients
    Wolfgang Dichtl
    Clinic for Internal Medicine III Cardiology, Medical University Innsbruck, Innsbruck, Austria
    Clin Cardiol 34:433-6. 2011
    ..Inappropriate implantable cardioverter defibrillator (ICD) shocks have been linked to a worse clinical outcome due to direct myocardial injury...
  48. ncbi Clinical ECG mapping and imaging of cardiac electrical excitation
    Bernhard Tilg
    Institute for Medical Signal Processing and Imaging, University for Health Informatics and Technology Tyrol, Innsbruck, Austria
    J Electrocardiol 35:81-7. 2002
    ..For focal arrhythmias, this model-based imaging approach might allow the guidance and evaluation of antiarrhythmic interventions, for instance, in case of catheter ablation or drug therapy...
  49. ncbi Lack of association between antimyelin antibodies and progression to multiple sclerosis
    Thomas Berger
    N Engl J Med 356:1888-9; author reply 1888-9. 2007
  50. ncbi A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions
    Hans Lassmann
    Division of Neuroimmunology, Brain Research Institute, University of Vienna, Austria
    Brain 126:1347-57. 2003
    ..The respective epitope is liberated into the CSF and, thus, may become a useful diagnostic tool to identify clinically a defined multiple sclerosis subtype...
  51. ncbi De novo aphasic status epilepticus as presenting symptom of multiple sclerosis
    Eugen Trinka
    J Neurol 249:782-3. 2002
  52. ncbi Antimyelin antibodies with no progression to multiple sclerosis
    Raul Pelayo
    N Engl J Med 356:426-8. 2007
  53. ncbi Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF
    Jens Kuhle
    Department of Neurology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 254:160-8. 2007
    ....
  54. ncbi Model-based imaging of cardiac electrical excitation in humans
    Bernhard Tilg
    Institute of Biomedical Engineering, Graz University of Technology
    IEEE Trans Med Imaging 21:1031-9. 2002
    ..The reconstructed sinus rhythm sequence was in good qualitative agreement with the pattern previously published for the isolated Langendorff-perfused human heart...
  55. ncbi Global P wave duration on the 65-lead ECG: single-site and dual-site pacing in the structurally normal human atrium
    Stefan Gozolits
    Department of Clinical Cardiology, University Hospital Innsbruck, Austria
    J Cardiovasc Electrophysiol 13:1240-5. 2002
    ..Pacing is believed to prevent atrial fibrillation by reducing atrial activation time. Exact correlation between P wave duration (PWD) on surface ECG and endocardial atrial activation time is still unexplored...
  56. ncbi [Tolerability and efficacy of a herbal combination preparation in children and adolescents with recurrent infections of the upper respiratory tract]
    Thomas Berger
    Facharzt für Kinder und Jugendmedizin, Frankfurt
    MMW Fortschr Med 150:85-90. 2008
  57. ncbi Neonatal kyphectomy in the patient with myelomeningocele
    Alvin H Crawford
    Department of Pediatric Orthopaedic Surgery, Children s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio 45229 3039, USA
    Spine (Phila Pa 1976) 28:260-6. 2003
    ..A retrospective cohort study was used to investigate a group of neonates with myelomeningocele who had a kyphectomy performed in conjunction with dural sac closure during the first few days of life...
  58. ncbi Atrial noninvasive activation mapping of paced rhythm data
    Robert Modre
    Institute for Medical Signal Processing and Imaging, University for Health Informatics and Technology Tyrol, Innrain 98, 6020 Innsbruck, Austria
    J Cardiovasc Electrophysiol 14:712-9. 2003
    ..Noninvasive imaging of electrical function in humans may be useful for computer-aided diagnosis and treatment of cardiac arrhythmias, which can be accomplished by the fusion of data from ECG mapping and magnetic resonance imaging (MRI)...
  59. ncbi Costs and quality of life of multiple sclerosis in Austria
    Gisela Kobelt
    Lund University, Lund, Sweden
    Eur J Health Econ 7:S14-23. 2006
    ..This loss increases to approximately 0.4 for patients over 60 years of age with an average EDSS score of 6.0-6.5. Patients with a recent relapse had lower utility (-0.1) and higher costs (+ euro 4.750)...
  60. ncbi Clinical predictors of health-related quality of life after pacemaker implantation
    Werner Benzer
    Department of Interventional Cardiology, Academic Hospital, Feldkirch, Austria
    Wien Klin Wochenschr 118:739-43. 2006
    ..The purpose of this study was to investigate the influence of clinical symptoms and ECG diagnoses as predictors of improved HRQL in patients referred for PMI...
  61. ncbi Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis
    Thomas Berger
    N Engl J Med 353:1744-6; author reply 1744-6. 2005